Recurrent and chronic pericarditis

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Recurrence is often immune-mediated, but the diagnostic threshold still matters. Symptoms can persist after inflammation resolves, while TB, malignancy and systemic disease can masquerade as idiopathic relapse.

The treatment principle is to extinguish objective inflammation and withdraw one drug at a time, slowly. Colchicine reduces recurrence; corticosteroid exposure and rapid tapers can create dependency.

CMR is particularly useful when conventional criteria are equivocal and in selecting anti-inflammatory escalation. Chronic effusion or constrictive physiology follows a different drainage/surgical pathway.

Key points

Recurrent pericarditis is a new episode after a documented first attack and a symptom-free interval, conventionally at least 4-6 weeks.
Incessant disease continues beyond 4-6 weeks without remission; chronic disease lasts beyond 3 months.
Do not label every recurrent chest pain inflammatory: document CRP rise, ECG/effusion change or CT/CMR inflammation when criteria are incomplete.
Recheck TB, bacterial, malignant, autoimmune, post-injury and drug causes when the course is atypical, systemic or treatment-resistant.
Aspirin/NSAID plus weight-adjusted colchicine for at least 6 months is usual first-line recurrent-disease therapy.
Avoid an early high-dose steroid reflex; if steroids are necessary, use low-to-moderate dose after excluding infection and taper only after complete remission.
Steroid-dependent, colchicine-resistant inflammatory disease may qualify for specialist IL-1 blockade; infection screening and a taper plan are mandatory.
Persistent effusion without inflammatory evidence is not treated automatically with repeated anti-inflammatory courses; reassess haemodynamics and cause.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Immune-mediated recurrence

After an apparently idiopathic or viral first episode, persistent innate immune activation can trigger renewed sterile pericardial inflammation despite no ongoing detectable infection.

Incomplete suppression or rapid withdrawal

A short initial course, premature taper or poor adherence may leave inflammation incompletely controlled. Early corticosteroid use and rapid tapering are associated with recurrence and treatment-dependent flares.

Infectious pericarditis

Tuberculosis and bacterial infection become especially important with fever, exposure, immunosuppression or a complicated effusion because immunosuppression could worsen an untreated pathogen.

Secondary systemic or cardiac disease

Autoimmune disease, malignancy, renal failure, post-cardiac injury and some medicines can sustain pericardial injury; an atypical or refractory course should prompt targeted investigation.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Pericardial injury
An infectious, immune, malignant, metabolic or post-injury trigger damages pericardial mesothelial surfaces and exposes inflammatory signals to the innate immune system.
2
Inflammatory activation
Cytokine-driven inflammation causes pericardial oedema, friction between inflamed layers and sometimes exudative fluid accumulation, producing positional pleuritic pain and systemic inflammatory markers.
3
Relapse or persistence
Persistent or renewed immune activation, including during treatment withdrawal, can produce recurrent flares; ongoing symptoms without objective inflammation may instead reflect non-inflammatory pain.
4
Effusive or fibrotic evolution
Continuing fluid production may create a chronic effusion, while repeated injury and healing can lead to adhesion, fibrosis, thickening or calcification.
5
Haemodynamic consequence
Rapid or excessive fluid accumulation can restrict chamber filling as tamponade; a rigid scarred pericardium can cause ventricular interdependence and chronic constrictive physiology.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

True inflammatory relapse

Return of typical pain with rub, ECG change, new/worsening effusion, CRP rise or pericardial oedema/LGE after remission.

Incessant course

Symptoms recur during taper or never fully settle for more than 4-6 weeks but less than 3 months.

Chronic phenotype

Disease beyond 3 months may be inflammatory, an isolated effusion or established constriction; distinguish these before escalating drugs.

Secondary-cause clues

Persistent fever, night sweats, weight loss, immunosuppression, cancer, TB exposure, renal failure, autoimmune features or post-procedure timing.

TamponadeRed flag

Rising JVP, tachycardia, pulsus paradoxus, hypotension or echo chamber collapse is an emergency irrespective of chronicity.

Constrictive evolutionRed flag

Ascites, oedema, Kussmaul sign, pericardial knock or ventricular interdependence needs specialist constriction assessment.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
CRP/ESR, FBC, U&E/eGFR and LFTFirst step
Why
Document inflammation and treatment safety; look for systemic clues.
Interpretation and limitations
Trend from flare to remission; a normal result with pain prompts imaging or a non-inflammatory differential rather than automatic escalation.
02
ECG and troponin
Why
Identify renewed electrical change, myocardial involvement and ACS alternative.
Interpretation and limitations
Troponin elevation or ventricular electrical instability changes the pathway to myopericarditis evaluation.
03
Serial TTE
Why
Track effusion and haemodynamics and screen constriction.
Interpretation and limitations
Effusion size alone does not define tamponade; a stable chronic effusion with no inflammation needs aetiological review rather than NSAID escalation.
04
CMR
Why
Confirm active inflammation and detect myocardial involvement or constriction.
Interpretation and limitations
Pericardial oedema/LGE can support a true flare and inform continued anti-inflammatory treatment when symptoms/CRP are discordant.
05
Targeted infection, autoimmune and malignancy testing
Why
Find a treatable secondary cause.
Interpretation and limitations
Select tests from exposure/systemic findings; blood cultures before antibiotics if febrile, and drain/biopsy when bacterial or neoplastic disease is plausible.
06
CT and/or invasive haemodynamics
Why
Assess calcification/thickening, loculated fluid or suspected constriction.
Interpretation and limitations
Normal pericardial thickness does not exclude constriction; catheterisation is reserved for unresolved restrictive-versus-constrictive uncertainty.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Non-inflammatory post-pericarditis pain

Persistent chest-wall, pleural or sensitisation pain without raised inflammatory markers, new effusion or imaging inflammation should not automatically be labelled another pericarditis flare.

Acute coronary syndrome

Pressure-like pain with regional ischaemic ECG change and a dynamic troponin rise favours acute myocardial ischaemia; pericarditis more often causes positional pain and widespread electrical change.

Myocarditis or myopericarditis

Troponin elevation, ventricular dysfunction or ventricular arrhythmia raises concern for myocardial involvement, which changes monitoring, exercise advice and the required imaging pathway.

Pulmonary embolism

New dyspnoea, hypoxaemia, haemoptysis, unilateral deep-vein signs or right-heart strain should prompt the pulmonary embolism pathway rather than assuming recurrent pericardial pain.

Pleural or musculoskeletal pain

Focal tenderness, pain reproducible by movement, cough or a local pleural process supports a non-pericardial source, particularly when inflammatory cardiac tests remain unchanged.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01RelapseFirst confirmed recurrenceFirst stepNew criteria or objective inflammation after remission.

1Recheck high-risk features and aetiology, adherence, prior dose/duration and whether a rapid taper or steroid exposure preceded relapse.
2Restart aspirin/ibuprofen at full anti-inflammatory dose with gastroprotection and add/continue weight-adjusted colchicine for at least 6 months.
3Restrict strenuous activity and review symptoms/CRP within 1-2 weeks; admit for high-risk features or myocardial involvement.
4After full clinical and CRP remission, taper NSAID/aspirin first; keep colchicine until last and avoid changing two drugs simultaneously.

02SteroidNSAID contraindication or defined systemic indicationFirst lineFirst-line agents unsafe/ineffective and infection excluded.

1Confirm objective inflammation and exclude TB, bacterial disease and untreated malignancy before immunosuppression.
2Use low-to-moderate prednisolone 0.2-0.5 mg/kg/day with colchicine rather than a high-dose burst; treat osteoporosis/infection risks as appropriate.
3Hold the dose until symptoms resolve and CRP normalises, then taper particularly slowly around 10-15 mg/day where relapses cluster.
4EscalationIf relapse occurs during taper, return to the last effective dose and seek specialist steroid-sparing advice rather than repeatedly escalating peaks.

03RefractoryColchicine-resistant, steroid-dependent inflammationDocumented recurrent flares despite adherence and an appropriate regimen.

1Refer to a pericardial-disease/rheumatology service; reconfirm inflammation by CRP/CMR and exclude infection, immune deficiency and secondary causes.
2Screen for TB/hepatitis and vaccination needs before IL-1 blockade; discuss off-label status, pregnancy, infection and neutropenia risk.
3A specialist may use anakinra or another IL-1 strategy, then taper steroids first and other anti-inflammatories sequentially after sustained remission.
4For relentless disease despite medical options or established constriction, discuss expert-centre pericardiectomy.

04ChronicPersistent effusion or suspected constrictionEffusion beyond 3 months, recurrent large fluid or right-HF physiology.

1Define inflammation and haemodynamics with CRP, echo and CMR/CT; investigate malignancy, TB, renal and systemic causes.
2Drain urgently for tamponade; consider diagnostic/therapeutic drainage for a large symptomatic, recurrent or suspicious effusion.
3If inflammatory transient constriction is present, use a time-limited anti-inflammatory trial with serial imaging; if fixed chronic constriction persists, refer early for pericardiectomy.

Key medicines and prescribing safety4 treatments · regimens, roles and cautions

Full-dose anti-inflammatory treatment during a recurrence, with gastroprotection.

Ibuprofen

600 mg orally three times daily initially, then taper by about 200 mg per dose each week only after symptom and CRP remission; maximum 2400 mg/day.

Renal injury, ulcer/bleeding, fluid retention, hypertension and late pregnancy; reassess anticoagulant and cardiovascular context.

Reduces further recurrences; the stated regimen is licensed for a UK oral solution, while the indication remains product-specific.

Colchicine

0.5 mg orally once daily at 70 kg or less, or 0.5 mg twice daily if over 70 kg, for at least 6 months in recurrent disease.

In mild or moderate renal or hepatic impairment use 0.5 mg once daily; severe impairment is contraindicated. Do not combine with strong CYP3A4/P-gp inhibitors when renal or hepatic function is impaired, and reduce or interrupt treatment even with normal function according to the interacting medicine. Monitor GI intolerance, cytopenia and myopathy.

Second-line/additional therapy when NSAID is contraindicated, a systemic indication exists or refractory disease is confirmed after infection exclusion.

Prednisolone

0.2-0.5 mg/kg orally once daily when specifically indicated; maintain to full remission, then taper slowly and especially cautiously below 15 mg/day.

Increases recurrence/dependency, infection, glucose, BP, bone and psychiatric risk; never use to mask untreated bacterial or TB pericarditis.

Steroid-sparing IL-1 blockade for selected colchicine-resistant, steroid-dependent inflammatory recurrent pericarditis.

Anakinra

Specialist off-label regimen 1-2 mg/kg subcutaneously once daily, maximum 100 mg/day, followed by a slow taper after sustained remission.

Screen for infection/TB and review vaccination; neutropenia, hepatic effects and injection reactions. Do not start during active serious infection.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Pericardial effusion and tamponade

Ongoing inflammation or an untreated secondary cause may lead to fluid accumulation. When intrapericardial pressure limits diastolic filling, hypotension and obstructive shock can develop rapidly.

Constrictive pericarditis

Repeated or severe inflammation can occasionally produce a non-compliant fibrotic pericardium, limiting ventricular filling and causing raised venous pressure, ascites, oedema and congestive organ dysfunction.

Myocardial involvement

Coexisting myocardial inflammation can cause ventricular dysfunction, troponin release or arrhythmia and requires a distinct myopericarditis assessment and follow-up pathway.

Treatment dependence and repeated relapse

Frequent reactivation, especially during corticosteroid tapering, can prolong immunosuppression, impair activity and quality of life, and expose patients to cumulative treatment adverse effects.

Progression of a secondary cause

Failure to recognise tuberculosis, bacterial infection, malignancy or systemic autoimmune disease can permit both pericardial deterioration and progression of the underlying illness.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Track pain, fever and CRP through each taper step; delay reduction if either remains active.
Monitor U&E/eGFR, BP, GI bleeding and fluid retention with NSAID therapy.
Review colchicine interactions, renal/hepatic function and toxicity symptoms at every medicine change.
With steroids, monitor glucose, BP, weight, mood, infection and bone protection; record cumulative exposure.
With anakinra, specialist monitoring includes FBC/neutrophils, LFT, infection and injection reactions.
Repeat TTE/CMR according to effusion, objective inflammation and suspected constriction, not pain alone.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Confirm the flare

Pain can persist from pleural, chest-wall or sensitisation mechanisms after inflammation resolves; CMR helps prevent endless immunosuppression.

One taper at a time

Withdraw steroids first, then NSAID/aspirin, with colchicine last so the effect of each change remains interpretable.

Steroid threshold

Relapses often occur around prednisolone 10-15 mg/day, so reductions here may need to be very small and widely spaced.

IL-1 blockade needs an exit strategy

Abrupt discontinuation can relapse; specialist taper follows sustained clinical, CRP and often imaging remission.

Chronic is not synonymous with inflammatory

A long-standing effusion can be non-inflammatory; repeated NSAIDs will not correct tamponade physiology or malignancy.

11Common pitfallsFrequent interpretation and management errors.

01
Calling pain alone a recurrent inflammatory episode without objective corroboration.
02
Giving a short high-dose steroid burst before excluding TB or bacterial disease.
03
Tapering steroids, NSAID and colchicine together.
04
Starting IL-1 blockade without infection screening and specialist follow-up.
05
Treating chronic effusion repeatedly with anti-inflammatories while missing tamponade, malignancy or constriction.